Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
Part of paid clinical trials in Berkeley, California.
- Sponsor
- University of California, Berkeley
- Study ID
- NCT06367738
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Aging
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - 85 Years
- Healthy Volunteers
- Accepted
Interventions
- Psilocybin — DRUGPsilocybin 1-30 mg
Study Details
Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults. After providing written informed consent, eligible participants, aged between 60 and 85, will be randomly assigned to receive a dose of psilocybin ranging from a microdose to a moderate-to-high dose. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity.
Key Dates
- Start date
- Nov 30, 2025
- Status verified
- Oct 2025
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2027
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Psilocybin Level 1The effects of different doses of psilocybin (1 - 10 mg) will be compared.
- Experimental: Psilocybin Level 2Psilocybin (11 - 20 mg) will be administered.
- Experimental: Psilocybin Level 3Psilocybin (21 - 30 mg) will be administered.
Primary Outcome Measure
MRI measurements of brain structure [ Time Frame: Baseline, week 1, and week 4 ]
Central Contacts
- BCSP Research Staff(669) 244-2436
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, Berkeley | Berkeley | California | 94720 |
Find similar trials in Berkeley, CA
Related Studies
- Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli OrisPHASE4 · Not Yet Recruiting · Amir Moradi MD, MBA · Vista, California
- Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's DiseaseRecruiting · Neurobehavioral Systems, Inc. · Berkeley, California
- Using Nicotine to Reverse Age-related Auditory Processing DeficitsRecruiting · University of California, Irvine · Irvine, California
- Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized EldersRecruiting · University of Michigan · Orange, California